Content Validation of the QOL-B-RD and PROMIS-F SF-7a to Measure Respiratory and Fatigue Symptoms of MAC Lung Disease

Overview

Journal Adv Ther

Date 2024 Dec 16

PMID 39680310

Authors

Kelly P McCarrier

Mariam Hassan

Dayton W Yuen

Jui-Hua Tsai

Nancy Touba

Kevin C Mange

Affiliations

Soon will be listed here.

Abstract

Introduction: The Quality of Life-Bronchiectasis (QOL-B) questionnaire and Patient Reported Outcome Measurement Information System Short Form v1.0-Fatigue 7a (PROMIS-F SF-7a) have the potential to measure respiratory and fatigue symptoms, respectively, in patients with Mycobacterium avium complex (MAC) lung disease but have not yet been evaluated for content validity in this population.

Methods: Semi-structured qualitative interviews were conducted in United States patients with a current MAC lung disease diagnosis. Concept elicitation (CE) interviews were conducted (n = 25 participants) to identify key respiratory and fatigue symptoms expressed as important and relevant to patients with MAC lung disease and to evaluate the appropriateness of the QOL-B and PROMIS-F SF-7a to measure these symptoms. Cognitive interviews (CIs) were subsequently conducted (n = 20 participants) to evaluate the relevance, comprehensibility, and appropriateness of the QOL-B respiratory domain (QOL-B-RD) and PROMIS-F SF-7a. All interviews were recorded, transcribed, and coded for qualitative content analysis.

Results: The most important or relevant respiratory symptom concepts to CE interview participants were "cough," "shortness of breath during activity," and "mucus/phlegm." The most important or relevant fatigue symptom concepts were "tiredness," "lack of energy," and "tire easily/low stamina." These symptoms are covered by existing items in the QOL-B-RD and PROMIS-F SF-7a. Cognitive interview participants' feedback confirmed the item content, response options, concept attributes, and recall period for each instrument were effective, relevant, and meaningful to most patients with MAC lung disease. Based on Wave 1 findings, the QOL-B instructions were revised for the Wave 2 interviews, where the text referencing "bronchiectasis" was replaced with "your lung condition." Participant feedback in Wave 2 confirmed the revised instruction wording was easily understood and appropriate.

Conclusions: The study results support the content validity of the QOL-B-RD and PROMIS-F SF-7a, which were shown to be relevant and appropriate to evaluate respiratory and fatigue symptoms, respectively, in patients with MAC lung disease.

References

Quittner A, ODonnell A, Salathe M, Lewis S, Li X, Montgomery A . Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores. Thorax. 2014; 70(1):12-20. DOI: 10.1136/thoraxjnl-2014-205918. View

Flume P, Griffith D, Chalmers J, Daley C, Olivier K, ODonnell A . Development of Drugs for Nontuberculous Mycobacterial Disease: Clinicians' Interpretation of a US Food and Drug Administration Workshop. Chest. 2020; 159(2):537-543. PMC: 8039007. DOI: 10.1016/j.chest.2020.08.2055. View

Kotilainen H, Valtonen V, Tukiainen P, Poussa T, Eskola J, Jarvinen A . Clinical findings in relation to mortality in non-tuberculous mycobacterial infections: patients with Mycobacterium avium complex have better survival than patients with other mycobacteria. Eur J Clin Microbiol Infect Dis. 2015; 34(9):1909-18. PMC: 4545189. DOI: 10.1007/s10096-015-2432-8. View

Lasch K, Marquis P, Vigneux M, Abetz L, Arnould B, Bayliss M . PRO development: rigorous qualitative research as the crucial foundation. Qual Life Res. 2010; 19(8):1087-96. PMC: 2940042. DOI: 10.1007/s11136-010-9677-6. View

Cook K, Bamer A, Roddey T, Kraft G, Kim J, Amtmann D . A PROMIS fatigue short form for use by individuals who have multiple sclerosis. Qual Life Res. 2011; 21(6):1021-30. PMC: 5609831. DOI: 10.1007/s11136-011-0011-8. View

Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S . The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol. 2010; 63(11):1179-94. PMC: 2965562. DOI: 10.1016/j.jclinepi.2010.04.011. View

Cella D, Lai J, Jensen S, Christodoulou C, Junghaenel D, Reeve B . PROMIS Fatigue Item Bank had Clinical Validity across Diverse Chronic Conditions. J Clin Epidemiol. 2016; 73:128-34. PMC: 4902759. DOI: 10.1016/j.jclinepi.2015.08.037. View

Lai J, Cella D, Choi S, Junghaenel D, Christodoulou C, Gershon R . How item banks and their application can influence measurement practice in rehabilitation medicine: a PROMIS fatigue item bank example. Arch Phys Med Rehabil. 2011; 92(10 Suppl):S20-7. PMC: 3696589. DOI: 10.1016/j.apmr.2010.08.033. View

Reeve B, Hays R, Bjorner J, Cook K, Crane P, Teresi J . Psychometric evaluation and calibration of health-related quality of life item banks: plans for the Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care. 2007; 45(5 Suppl 1):S22-31. DOI: 10.1097/01.mlr.0000250483.85507.04. View

10.

Hama M, Ushiki A, Kosaka M, Yamazaki Y, Yasuo M, Yamamoto H . Health-related quality of life in patients with pulmonary non-tuberculous mycobacteria infection. Int J Tuberc Lung Dis. 2016; 20(6):747-52. DOI: 10.5588/ijtld.15.0460. View

11.

Quittner A, Marciel K, Salathe M, ODonnell A, Gotfried M, Ilowite J . A preliminary quality of life questionnaire-bronchiectasis: a patient-reported outcome measure for bronchiectasis. Chest. 2014; 146(2):437-448. DOI: 10.1378/chest.13-1891. View

12.

Mehta M, Marras T . Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease. Respir Med. 2011; 105(11):1718-25. DOI: 10.1016/j.rmed.2011.08.004. View

13.

Griffith D, Aksamit T, Brown-Elliott B, Catanzaro A, Daley C, Gordin F . An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007; 175(4):367-416. DOI: 10.1164/rccm.200604-571ST. View

14.

Yount S, Atwood C, Donohue J, Hays R, Irwin D, Leidy N . Responsiveness of PROMIS® to change in chronic obstructive pulmonary disease. J Patient Rep Outcomes. 2019; 3(1):65. PMC: 6820639. DOI: 10.1186/s41687-019-0155-9. View

15.

van Ingen J, Obradovic M, Hassan M, Lesher B, Hart E, Chatterjee A . Nontuberculous mycobacterial lung disease caused by complex - disease burden, unmet needs, and advances in treatment developments. Expert Rev Respir Med. 2021; 15(11):1387-1401. DOI: 10.1080/17476348.2021.1987891. View

16.

Daley C, Iaccarino J, Lange C, Cambau E, Wallace Jr R, Andrejak C . Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis. 2020; 71(4):e1-e36. PMC: 7768748. DOI: 10.1093/cid/ciaa241. View

17.

Adjemian J, Olivier K, Seitz A, Holland S, Prevots D . Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012; 185(8):881-6. PMC: 3360574. DOI: 10.1164/rccm.201111-2016OC. View

18.

Kim R, Greenberg D, Ehrmantraut M, Guide S, Ding L, Shea Y . Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med. 2008; 178(10):1066-74. PMC: 2720143. DOI: 10.1164/rccm.200805-686OC. View

19.

Gruet M . Fatigue in Chronic Respiratory Diseases: Theoretical Framework and Implications For Real-Life Performance and Rehabilitation. Front Physiol. 2018; 9:1285. PMC: 6156387. DOI: 10.3389/fphys.2018.01285. View

20.

Johnson M, ODell J . Nontuberculous mycobacterial pulmonary infections. J Thorac Dis. 2014; 6(3):210-20. PMC: 3949190. DOI: 10.3978/j.issn.2072-1439.2013.12.24. View